MacroGenics - MGNX Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $11.20
Forecasted Upside: 57.30%
Number of Analysts: 11
Breakdown:
0 Sell Ratings
5 Hold Ratings
6 Buy Ratings
0 Strong Buy Ratings

^$7.12 As of 03/30/2023 01:00 AM ET

▼ -0.12 (-1.66%)

1 month | 3 months | 12 months

Get New MacroGenics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for MGNX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MGNX

^$11.20

▲ +57.30% Upside Potential

This price target is based on 11 analysts offering 12 month price targets for MacroGenics in the last 3 months. The average price target is $11.20, with a high forecast of $17.00 and a low forecast of $5.00. The average price target represents a 57.30% upside from the last price of $7.12.

Current Consensus is Buy

The current consensus among 11 investment analysts is to buy stock in MacroGenics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
5 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

10/6/2021

0 strong buy ratings
6 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

1/4/2022

0 strong buy ratings
6 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

4/4/2022

0 strong buy ratings
4 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

7/3/2022

0 strong buy ratings
5 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

10/1/2022

0 strong buy ratings
5 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

12/30/2022

0 strong buy ratings
5 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

2/28/2023

0 strong buy ratings
6 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

3/30/2023

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/21/2023	BTIG Research	Boost Target	Buy	$6.00 ➝ $12.00	Low
3/20/2023	Citigroup	Boost Target		$7.00 ➝ $8.00	Low
3/20/2023	HC Wainwright	Boost Target		$12.00 ➝ $14.00	Low
3/17/2023	Guggenheim	Reiterated Rating	Buy ➝ Neutral		Low
3/16/2023	JMP Securities	Reiterated Rating	Market Outperform	$8.00	Low
3/9/2023	Stifel Nicolaus	Boost Target		$15.00 ➝ $17.00	Low
1/19/2023	JMP Securities	Lower Target	Market Outperform	$18.00 ➝ $8.00	Low
11/23/2022	Citigroup	Downgrade	Buy ➝ Neutral	$16.00 ➝ $7.00	Low
11/22/2022	Guggenheim	Upgrade	Neutral ➝ Buy	$12.00	Low
11/22/2022	Cowen	Downgrade	Outperform ➝ Market Perform		Low
11/22/2022	Cowen	Downgrade	Outperform ➝ Market Perform		Low
11/14/2022	BMO Capital Markets	Upgrade	Market Perform ➝ Outperform	$5.70 ➝ $16.00	Low
11/7/2022	HC Wainwright	Boost Target	Buy	$11.00 ➝ $12.00	Low
10/18/2022	HC Wainwright	Boost Target	Buy	$10.00 ➝ $11.00	N/A
9/12/2022	HC Wainwright	Lower Target	Buy	$35.00 ➝ $10.00	Low
8/29/2022	Citigroup	Boost Target	Buy	$13.00 ➝ $16.00	Low
8/15/2022	Barclays	Lower Target		$8.00	N/A
8/9/2022	SVB Leerink	Lower Target	Outperform	$15.00 ➝ $12.00	Low
8/9/2022	Barclays	Lower Target	Overweight	$18.00 ➝ $8.00	Low
7/19/2022	BTIG Research	Set Target		$6.00	Low
7/18/2022	Sumitomo Mitsui Financial Group	Downgrade	Outperform ➝ Neutral	$5.00	Low
7/12/2022	JMP Securities	Lower Target	Market Outperform	$24.00 ➝ $20.00	N/A
7/11/2022	BTIG Research	Lower Target		$6.00	N/A
7/11/2022	BMO Capital Markets	Downgrade	Outperform ➝ Market Perform	$31.00 ➝ $4.00	N/A
5/4/2022	Guggenheim	Downgrade	Buy ➝ Neutral		High
5/4/2022	HC Wainwright	Lower Target		$41.00 ➝ $35.00	High
2/28/2022	Citigroup	Upgrade	Neutral ➝ Buy	$23.00 ➝ $21.00	High
2/25/2022	Barclays	Lower Target		$35.00 ➝ $18.00	High
2/25/2022	SVB Leerink	Lower Target	Outperform	$40.00 ➝ $23.00	High
2/11/2022	BMO Capital Markets	Initiated Coverage	Outperform	$31.00	High
2/4/2022	Sumitomo Mitsui Financial Group	Initiated Coverage	Outperform	$40.00	Low
11/17/2021	Guggenheim	Initiated Coverage	Buy	$30.00	High
11/3/2021	JMP Securities	Lower Target	Market Outperform	$39.00 ➝ $38.00	High
10/19/2021	JMP Securities	Initiated Coverage	Outperform	$39.00	Low
9/20/2021	HC Wainwright	Reiterated Rating	Buy	$41.00	Low
9/19/2021	SVB Leerink	Reiterated Rating	Buy		Medium
7/27/2021	HC Wainwright	Reiterated Rating	Buy	$41.00	Medium
6/17/2021	HC Wainwright	Reiterated Rating	Buy		Low
6/16/2021	BTIG Research	Initiated Coverage	Buy		Medium
6/7/2021	Wedbush	Lower Target	Outperform	$39.00 ➝ $34.00	High
4/30/2021	SVB Leerink	Boost Target	Outperform	$37.00 ➝ $40.00	High
4/30/2021	HC Wainwright	Boost Target	Buy	$36.00 ➝ $41.00	High
4/26/2021	Morgan Stanley	Boost Target	Underweight	$16.00 ➝ $17.00	N/A
4/19/2021	Morgan Stanley	Boost Target	Underweight	$15.00 ➝ $16.00	Medium
3/12/2021	Barclays	Upgrade	Underweight ➝ Overweight	$14.00 ➝ $40.00	High
3/4/2021	Morgan Stanley	Boost Target	Underweight	$14.00 ➝ $15.00	N/A
2/26/2021	Morgan Stanley	Boost Target	Underweight	$14.00 ➝ $15.00	High
12/22/2020	HC Wainwright	Reiterated Rating	Buy	$36.00	Low
12/17/2020	Barclays	Boost Target	Underweight	$8.00 ➝ $14.00	High
11/13/2020	Morgan Stanley	Boost Target	Underweight	$13.00 ➝ $14.00	Low
11/5/2020	SVB Leerink	Lower Target	Outperform	$38.00 ➝ $37.00	High
10/13/2020	Morgan Stanley	Boost Target	Underweight	$12.00 ➝ $13.00	Low
9/21/2020	SVB Leerink	Boost Target	Outperform	$35.00 ➝ $38.00	High
8/3/2020	Citigroup	Downgrade	Buy ➝ Neutral	$25.00 ➝ $26.00	High
7/31/2020	Morgan Stanley	Boost Target	Underweight	$11.00 ➝ $12.00	High
7/31/2020	HC Wainwright	Reiterated Rating	Buy	$40.00	High
7/15/2020	Morgan Stanley	Boost Target	Underweight	$6.00 ➝ $11.00	Low
6/2/2020	Citigroup	Boost Target		$15.00 ➝ $25.00	Low
6/1/2020	Guggenheim	Upgrade	Neutral ➝ Buy		Low
5/29/2020	SVB Leerink	Boost Target	Outperform	$15.00 ➝ $27.00	Medium
5/29/2020	Stifel Nicolaus	Boost Target	Buy	$21.00 ➝ $36.00	High
5/28/2020	BTIG Research	Boost Target	Buy	$23.00 ➝ $35.00	High
5/26/2020	HC Wainwright	Boost Target	Buy	$22.00 ➝ $40.00	High
5/17/2020	Nomura	Reiterated Rating	Buy	$50.00	Low
5/14/2020	Wedbush	Boost Target	Outperform	$16.00 ➝ $28.00	Medium
5/12/2020	Credit Suisse Group	Boost Target	Outperform	$13.00 ➝ $30.00	High
5/6/2020	Wedbush	Reiterated Rating	Outperform		High
5/6/2020	Credit Suisse Group	Lower Target	Outperform	$17.00 ➝ $13.00	High
5/6/2020	SVB Leerink	Lower Target	Outperform	$16.00 ➝ $15.00	High
5/6/2020	HC Wainwright	Boost Target	Buy	$18.00 ➝ $22.00	High
3/4/2020	Barclays	Initiated Coverage	Underweight	$8.00	Medium
3/2/2020	Credit Suisse Group	Lower Target	Outperform	$26.00 ➝ $17.00	Low
2/26/2020	HC Wainwright	Reiterated Rating	Buy	$18.00	High
2/26/2020	Stifel Nicolaus	Lower Target	Buy	$21.00 ➝ $20.00	High
2/26/2020	Citigroup	Lower Target	Buy	$18.00 ➝ $15.00	High
1/21/2020	Wedbush	Boost Target	Outperform	$14.00 ➝ $16.00	High
12/20/2019	HC Wainwright	Reiterated Rating	Buy	$18.00	High
12/18/2019	Cantor Fitzgerald	Initiated Coverage	Overweight	$17.00	Medium
12/12/2019	BTIG Research	Reiterated Rating	Buy ➝ Positive	$23.00	High
12/12/2019	Nomura Securities	Reiterated Rating	Buy	$50.00	High
12/10/2019	HC Wainwright	Reiterated Rating	Buy	$18.00	High
12/10/2019	Cowen	Reiterated Rating	Buy		N/A
11/21/2019	Morgan Stanley	Downgrade	Equal ➝ Equal Weight	$17.00 ➝ $6.00	High
11/20/2019	Guggenheim	Initiated Coverage	Hold		High
11/7/2019	Citigroup	Lower Target	Buy	$39.00 ➝ $18.00	Low
10/23/2019	HC Wainwright	Lower Target	Buy	$39.00 ➝ $18.00	High
10/23/2019	SVB Leerink	Lower Target	Outperform	$26.00 ➝ $18.00	High
10/23/2019	Wedbush	Lower Target	Outperform	$23.00 ➝ $14.00	High
8/1/2019	Stifel Nicolaus	Lower Target	Buy	$29.00 ➝ $25.00	High
7/18/2019	Wedbush	Reiterated Rating	Outperform	$27.00	Low
6/5/2019	Morgan Stanley	Set Target	Hold	$19.00	Low
6/5/2019	Stifel Nicolaus	Lower Target	Buy	$36.00 ➝ $29.00	Low
6/5/2019	Wedbush	Reiterated Rating	Outperform	$26.00 ➝ $27.00	High
6/5/2019	Cowen	Reiterated Rating	Buy		High
5/3/2019	Wedbush	Upgrade	Neutral ➝ Outperform	$26.00	Low
5/2/2019	HC Wainwright	Reiterated Rating	Buy	$39.00	High
5/2/2019	Cowen	Reiterated Rating	Buy		High
4/17/2019	Credit Suisse Group	Initiated Coverage	Outperform	$29.00	High
4/12/2019	Guggenheim	Initiated Coverage	Neutral		Medium
4/4/2019	HC Wainwright	Reiterated Rating	Buy	$39.00	Medium
2/20/2019	HC Wainwright	Set Target	Buy	$39.00	Low
2/7/2019	Nomura Securities	Boost Target	Buy	$41.00 ➝ $50.00	Medium
2/7/2019	SunTrust Banks	Boost Target	Buy	$40.00	High
2/7/2019	Wedbush	Downgrade	Outperform ➝ Neutral		High
2/7/2019	Citigroup	Upgrade	Sell ➝ Buy	$10.00 ➝ $39.00	High
2/6/2019	Raymond James	Upgrade	Underperform ➝ Market Perform	$26.80	High
2/6/2019	HC Wainwright	Reiterated Rating	Positive ➝ Buy	$34.00 ➝ $39.00	High
2/4/2019	Citigroup	Downgrade	Neutral ➝ Sell	$22.00 ➝ $10.00	High
1/22/2019	Wedbush	Reiterated Rating	Outperform ➝ Positive	$44.00 ➝ $20.00	High
1/21/2019	Raymond James	Reiterated Rating	Sell		High
12/10/2018	Morgan Stanley	Set Target	Hold	$21.00	High
12/10/2018	Raymond James	Downgrade	Outperform ➝ Underperform		High
12/5/2018	HC Wainwright	Set Target	Buy	$34.00	High
11/29/2018	HC Wainwright	Set Target	Buy	$34.00	High
11/8/2018	HC Wainwright	Set Target	Buy	$34.00	High
10/30/2018	HC Wainwright	Reiterated Rating	Buy	$34.00	Medium
9/10/2018	BTIG Research	Initiated Coverage	Buy ➝ Buy	$30.00	Low
8/8/2018	Cowen	Reiterated Rating	Buy		Medium
8/8/2018	HC Wainwright	Reiterated Rating	Buy	$34.00	High
6/4/2018	HC Wainwright	Set Target	Buy	$34.00	Low
5/31/2018	Evercore ISI	Initiated Coverage	Outperform	$33.00	Medium
5/8/2018	Wedbush	Reiterated Rating	Outperform	$44.00	High
5/8/2018	HC Wainwright	Set Target	Buy	$34.00	High
4/6/2018	SVB Leerink	Reiterated Rating	Outperform		High

(Data available from 3/30/2018 forward)

News Sentiment Rating

0.86 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

2 very positive mentions
11 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

9/1/2022

1 very positive mentions
7 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

10/1/2022

4 very positive mentions
13 positive mentions
3 negative mentions
3 very negative mentions

Mentions as of

10/31/2022

4 very positive mentions
8 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

11/30/2022

0 very positive mentions
2 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

12/30/2022

3 very positive mentions
3 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

1/29/2023

3 very positive mentions
1 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

2/28/2023

11 very positive mentions
11 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

3/30/2023

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

MacroGenics, Inc. is a clinical-stage biopharmaceutical company engaged in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

Today's Range

Now: $7.12

$6.87

$7.33

50 Day Range

MA: $6.13

$4.82

$7.24

52 Week Range

Now: $7.12

$2.13

$10.20

Volume

434,171 shs

Average Volume

692,924 shs

Market Capitalization

$440.30 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.97

Frequently Asked Questions

What sell-side analysts currently cover shares of MacroGenics?: The following sell-side analysts have issued stock ratings on MacroGenics in the last twelve months: Barclays PLC, BMO Capital Markets, BTIG Research, Citigroup Inc., Cowen Inc, Cowen Inc., Guggenheim, HC Wainwright, JMP Securities, Stifel Nicolaus, StockNews.com, Sumitomo Mitsui Financial Group, Inc., and SVB Leerink LLC.
View the latest analyst ratings for MGNX.
What is the current price target for MacroGenics?: 10 Wall Street analysts have set twelve-month price targets for MacroGenics in the last year. Their average twelve-month price target is $11.20, suggesting a possible upside of 61.8%. Stifel Nicolaus has the highest price target set, predicting MGNX will reach $17.00 in the next twelve months. Sumitomo Mitsui Financial Group, Inc. has the lowest price target set, forecasting a price of $5.00 for MacroGenics in the next year.
View the latest price targets for MGNX.
What is the current consensus analyst rating for MacroGenics?: MacroGenics currently has 5 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MGNX will outperform the market and that investors should add to their positions of MacroGenics.
View the latest ratings for MGNX.
What other companies compete with MacroGenics?: Other companies that are similar to MacroGenics include Lexicon Pharmaceuticals, Erasca, Karyopharm Therapeutics, Terns Pharmaceuticals and Edgewise Therapeutics. Learn More about companies similar to MacroGenics.
How do I contact MacroGenics' investor relations team?: MacroGenics' physical mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company's listed phone number is (301) 251-5172 and its investor relations email address is [email protected] The official website for MacroGenics is www.macrogenics.com. Learn More about contacing MacroGenics investor relations.

MacroGenics - MGNX Stock Price Target and Predictions

Analyst Price Target for MGNX

Current Consensus is Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.86 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of MacroGenics?

What is the current price target for MacroGenics?

What is the current consensus analyst rating for MacroGenics?

What other companies compete with MacroGenics?

How do I contact MacroGenics' investor relations team?